Neurogene Inc. (NGNE) Research

Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.

Market snapshot

Symbol
NGNE
Price
$31.53
Day change
+2.40%
Market cap
$498.2M
P/E ratio
-7.13x
52-week range
14.65-37.266
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$69.67

Peer companies

  • ADC Therapeutics S.A. (ADCT)
  • Alumis Inc. Common Stock (ALMS)
  • Autolus Therapeutics plc (AUTL)
  • Benitec Biopharma Inc. (BNTC)
  • Fulcrum Therapeutics, Inc. (FULC)
  • Lineage Cell Therapeutics, Inc. (LCTX)
  • Ocugen, Inc. (OCGN)
  • PureTech Health plc (PRTC)

Recent insider activity

  • Woods Keith — A-Award (15400 shares) on 2024-01-16
  • Woods Keith — A-Award (7700 shares) on 2024-06-14
  • Woods Keith — A-Award (12050 shares) on 2025-06-12
  • Woods Keith — trade (0 shares) on 2023-12-18
  • Cvijic Christine Mikail — S-Sale (4800 shares) on 2026-05-06

Open Neurogene Inc. (NGNE) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.